Therefore, we conducted a comprehensive three‐stage, three‐cohort retrospective study to explore the survival outcomes of EGFR‐mutant NSCLC patients with BMs using Kaplan–Meier and Cox regression analyses. This evidence concerns the gene EGFR and non-small cell lung carcinoma.